Currentblue cross blue shield - louisianaPolicy MA-213

tocilizumab intravenous Products

Customize your policy alerts

Sign up for blue cross blue shield - louisiana Policy MA-213 alerts

Get alerted when Policy MA-213 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical policy governing coverage eligibility and clinical criteria for intravenous tocilizumab products (including Actemra and listed biosimilars) for multiple indications; applies to Blue Cross Blue Shield - Louisiana members and providers administering these products.

Policy Summary

Payerblue cross blue shield - louisiana

Policytocilizumab intravenous Products

Policy CodePolicy MA-213

Change TypeNo material changes

Effective DateJul 1, 2026

Last ReviewApr 21, 2026

Next Review DateApr 21, 2026

Key ActionObtain prior authorization for initial and continuation therapy and document clinical benefit for continuation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6eligible indications

2 yrsminimum age (JIA/CRS)

8 mg/kgmax adult dose (q4w)

6 mg/kgGCA dosing

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Currentblue cross blue shield - louisianaPolicy MA-213

tocilizumab intravenous Products

Customize your policy alerts

Sign up for blue cross blue shield - louisiana Policy MA-213 alerts

Get alerted when Policy MA-213 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payerblue cross blue shield - louisiana

Policytocilizumab intravenous Products

Policy CodePolicy MA-213

Change TypeNo material changes

Effective DateJul 1, 2026

Last ReviewApr 21, 2026

Next Review DateApr 21, 2026

Key ActionObtain prior authorization for initial and continuation therapy and document clinical benefit for continuation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6eligible indications

2 yrsminimum age (JIA/CRS)

8 mg/kgmax adult dose (q4w)

6 mg/kgGCA dosing

Coverage Criteria for Intravenous Tocilizumab

Rheumatoid Arthritis — Initial and Continuation Therapy

Covered when ALL of the following are met

Age: Initial: Patient is 18 years of age or older>=18 years

Diagnosis: Patient has a diagnosis of moderately to severely active rheumatoid arthritis

Prior therapy: Failed treatment with one or more traditional disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, unless contraindicated

Concomitant therapy restriction: Requested drug is NOT given concomitantly with other biologic DMARDs (eg, adalimumab, etanercept) or other specified agents (eg, apremilast, tofacitinib)

TB screening: Patient has a negative tuberculosis (TB) test (eg, PPD or blood test) prior to treatment

Dose limit: Dose does not exceed 8 mg/kg every 4 weeks<=8 mg/kg q4w

Continuation prerequisites: Continuation: patient has received initial authorization from the plan OR documentation of authorization for an active course of treatment from a previous health plan; AND patient has experienced a beneficial clinical response from baseline (eg, decreased joint pain, morning stiffness, improved function, decreased soft tissue swelling); AND requested drug is NOT used in combination with other biologic DMARDs or specified agents; AND dose does not exceed 8 mg/kg every 4 weeks

Systemic Juvenile Idiopathic Arthritis — Initial and Continuation Therapy

Covered when ALL of the following are met

Age: Initial: Patient is 2 years of age and older>=2 years

Diagnosis: Patient has a diagnosis of active systemic juvenile idiopathic arthritis

Prior therapy: Inadequate clinical response to NSAIDs or corticosteroids unless contraindicated

Concomitant therapy restriction: Requested drug is NOT given concomitantly with other biologic DMARDs or specified agents (eg, adalimumab, etanercept, apremilast, tofacitinib)

Polyarticular Juvenile Idiopathic Arthritis — Initial and Continuation Therapy

Covered when ALL of the following are met

Age: Initial: Patient is 2 years of age and older>=2 years

Diagnosis: Patient has a diagnosis of active polyarticular juvenile idiopathic arthritis

Prior therapy: Failed treatment with one or more traditional DMARDs (eg, methotrexate) unless contraindicated

Concomitant therapy restriction: Requested drug is NOT given concomitantly with other biologic DMARDs or specified agents (eg, adalimumab, etanercept, apremilast, tofacitinib)

Giant Cell Arteritis — Initial and Continuation Therapy

Covered when ALL of the following are met

Diagnosis: Patient has a diagnosis of giant cell arteritis

Age: Patient is 18 years of age or older>=18 years

Concomitant glucocorticoids: Requested drug used in combination with a tapering course of glucocorticoids

TB screening: Patient has a negative TB test (eg, PPD or blood test) prior to treatment

Prior therapy:

Cytokine Release Syndrome

Coverage stance: Health Plan may consider intravenous tocilizumab products for treatment of cytokine release syndrome to be eligible for coverage

Cytokine Release Syndrome — Covered when ALL of the following are met

Covered when ALL of the following are met:

Age and diagnosis: Patient is 2 years of age or older AND has a diagnosis of CAR T cell–induced severe or life‑threatening cytokine release syndrome (defined as hemodynamic instability despite IV fluids and vasopressor support OR worsening respiratory distress including pulmonary infiltrates, increasing oxygen requirement including high‑flow oxygen and/or need for mechanical ventilation OR rapid clinical deterioration)

Dose and frequency limits: No more than 4 total IV doses of tocilizumab should be administered per CRS event; no single infusion should exceed 800 mg; interval between infusions should be at least 8 hours<=4 total doses per event; max 800 mg/infusion; >=8 hours between infusions

Dosing by weight: Dosing follows weight‑based recommendations: patients <30 kg: 12 mg/kg per dose; patients >=30 kg: 8 mg/kg per dose (with maximum 800 mg per infusion)

Continuation Therapy — continuation coverage criteria

Continuation covered when ALL of the following are met:

Authorization documentation: Patient received initial authorization for the requested drug from the plan OR has documentation of authorization for an active course of treatment from a previous health plan

Clinical benefit: Patient has experienced a beneficial clinical response from baseline as evidenced by indication‑specific improvements (eg, decreased headache/scalp/jaw pain, reduced fatigue, improved vision, reduced corticosteroid dose, or improved inflammatory markers for giant cell arteritis; or joint symptom improvement for rheumatoid arthritis; or resolution of fever and normalization of inflammatory markers for systemic JIA)evidence of clinical benefit

Concomitant therapy restriction: Requested drug is NOT given concomitantly with other biologic DMARDs or specified agents (eg, adalimumab, etanercept, apremilast, tofacitinib)

Arthritis Indications — specific arthritis indication criteria grouped

Covered when ALL of the following are met for the specific arthritis indications:

Rheumatoid Arthritis Initial Criteria: For rheumatoid arthritis, patient meets policy selection criteria (eg, age, diagnosis, prior DMARD failure) and for continuation must have experienced beneficial clinical response (eg, decreased joint pain, morning stiffness, improved function, decreased soft tissue swelling)

Polyarticular JIA Criteria: For polyarticular juvenile idiopathic arthritis, patient meets selection criteria including failure of one or more traditional DMARDs; continuation requires demonstrated clinical benefit (eg, improved range of motion, reduced pain, decreased morning stiffness, improved function, decreased corticosteroid dose, improved inflammatory markers); AND weight‑based dosing applied

Systemic JIA Criteria: For systemic juvenile idiopathic arthritis, patient had inadequate response to NSAIDs or corticosteroids prior to tocilizumab; continuation requires demonstrated clinical benefit (eg, resolution of fever, reduced rash, normalization of inflammatory markers, decreased corticosteroid needs, reduced joint symptoms)

Giant Cell Arteritis — covered when ALL of the following are met (alternate chunk set)

Covered when ALL of the following are met:

Diagnosis and prior therapy: Patient has giant cell arteritis and has failed treatment with systemic corticosteroid therapy unless contraindicated or there is clinical evidence steroids will be ineffective or cause harm

Dosing and combination: Dosing consistent with regimen (eg, IV 6 mg/kg every 4 weeks OR SC 162 mg weekly in combination with a steroid taper); AND continuation requires documented beneficial clinical response (eg, decreased headache, scalp or jaw pain, reduced fatigue, improved vision, reduced corticosteroid dosage, or improved inflammatory markers)

Diagnostic considerations: Temporal artery biopsy is diagnostic gold standard but clinical suspicion may warrant initiation of steroid therapy prior to confirmation

Covered Indications and Requirements — consistency with FDA indications and policy evidence

Covered when consistent with FDA-approved indications and supported evidence described in the policy

FDA Indication Alignment: Treatment is for an FDA‑approved indication for intravenous tocilizumab (rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, systemic sclerosis‑associated interstitial lung disease, and hospitalized COVID‑19 where approved)

Efficacy Evidence: Clinical trials or pooled analyses described in the policy support efficacy for the indication (eg, ACR response rates for RA; JIA ACR30 and other trial endpoints for systemic and polyarticular JIA; pooled CAR‑T data for CRS)

Prior Authorization: Prior authorization is required for all codes listed on the Medical Policy

Investigational or experimental services, including drugs provided under the investigational arm of a clinical trial or for indications not addressed by the FDA, are not covered by the Health Plan unless coverage is specifically mandated by CMS. Coverage for routine services in certain IDE studies is limited as described in the policy. Use of tocilizumab products when patient selection criteria in this policy are not met may be considered investigational (see specific exclusions below).

Requests may be denied if the member’s benefits do not include coverage for investigational treatments or if medical necessity requirements in this policy are not satisfied.

Use of tocilizumab in indications or dosage forms that are not FDA‑approved is considered investigational and is not covered. Examples explicitly noted in the policy include intravenous use for systemic sclerosis‑associated interstitial lung disease and subcutaneous use for COVID‑19, as well as outpatient use of intravenous tocilizumab for COVID‑19.

Providers should confirm the formulation and indication requested are among those supported by the policy and FDA approvals; requests for non‑approved forms or indications should be expected to be denied as investigational.

Although multiple intravenous tocilizumab biosimilars are listed with indications largely aligned to Actemra, the policy notes that Tofidence does not carry the cytokine release syndrome (CRS) or systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) indications. Providers must verify the biosimilar product requested supports the specific indication before requesting authorization.

Dosing that exceeds the policy’s specified limits for each indication is not covered. Examples of the stated thresholds include ≤8 mg/kg every 4 weeks for adult rheumatoid arthritis, ≤12 mg/kg every 2 weeks for systemic JIA patients <30 kg, ≤10 mg/kg every 4 weeks for polyarticular JIA patients <30 kg, and a maximum of 800 mg per infusion for cytokine release syndrome with no more than four total infusions per CRS event.

Prior authorization will require documentation that ordered doses are within these maximums; requests that propose doses beyond these limits should be expected to be denied as not meeting policy dosing criteria.

Use of tocilizumab is considered not medically necessary when required disease‑specific patient selection criteria or continuation criteria listed in the policy are not met. For continuation requests, the plan requires documentation of prior authorization (from this plan or a previous plan) and evidence of a beneficial clinical response from baseline as specified for the indication.

Examples of unmet criteria that would render use not medically necessary include failure to demonstrate prior trial of indicated conventional therapies (where required), lack of documented clinical improvement during prior therapy, concomitant use with prohibited biologic DMARDs, or dosing outside the policy limits.

For the purposes of this policy, investigational therapies are those not supported by sufficient credible evidence or not FDA‑approved for the requested indication or dosage form; investigational uses are not covered unless CMS requirements mandate coverage. Medically necessary services are those that meet nationally accepted standards of medical practice, are clinically appropriate in type, frequency, extent and duration, and are not primarily for convenience or more costly than an alternative of equivalent effectiveness.

Decisions about investigational versus medically necessary status will be based on FDA approval status, the policy’s clinical selection and continuation criteria, and the presence of peer‑reviewed evidence or specialty society guidance as described in the policy’s coding and clinical rationale sections.

Coding and Dosing Information

Covered HCPCS (example from payer context)HCPCSCovered

J3262

Injection, tocilizumab, 10 mg (example billing code cited by payer policy context)

HCPCS codesHCPCSCovered

J3262	tocilizumab (per document listing)
Q5133	tocilizumab biosimilar (per document listing)
Q5135	tocilizumab biosimilar (per document listing)
Q5156	tocilizumab biosimilar (per document listing)

ICD-10 DiagnosisICD-10

All related diagnoses

ICD-10 diagnoses related to indications for tocilizumab

inv-20: Maximum dosing per indication — summarized dose limits and examples

Adult rheumatoid arthritisMaximum 8 mg/kg IV every 4 weeks

Polyarticular juvenile idiopathic arthritis (<30 kg)Maximum 10 mg/kg IV every 4 weeks

Polyarticular juvenile idiopathic arthritis (>=30 kg)Maximum 8 mg/kg IV every 4 weeks

Systemic juvenile idiopathic arthritis (<30 kg)Maximum 12 mg/kg IV every 2 weeks

Systemic juvenile idiopathic arthritis (>=30 kg)Maximum 8 mg/kg IV every 2 weeks

Giant cell arteritisDosage 6 mg/kg IV every 4 weeks

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior authorization required — initial and continuation; include documentation

Obtain prior authorization for both initial and continuation IV tocilizumab therapy. For continuation requests, provide evidence that the patient received initial authorization from this plan OR documentation of authorization for an active course of treatment from a previous health plan, plus evidence of clinical benefit from baseline.

Initial and continuation therapy require prior authorization.
Continuation requires documentation of prior plan authorization OR initial authorization from this plan.
Include evidence of clinical benefit from baseline (indication-specific outcomes).

Prior Authorization

Continuation authorization requires prior plan authorization or documentation of active course

For continuation, submit either the plan's prior authorization for the initial course OR documentation from the previous health plan showing authorization for an active course of treatment; include clinical response data demonstrating benefit.

Background and Scope

Tocilizumab intravenous products (Actemra and its listed biosimilars) are targeted interleukin‑6 receptor antagonists used to treat multiple inflammatory conditions. The FDA‑approved intravenous indications referenced in the policy include rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, systemic sclerosis‑associated interstitial lung disease, and hospitalized COVID‑19 where indicated. The policy also notes the approval history and that biosimilars (for example, Tofidence, Tyenne, Avtozma) have been approved with varying indication coverage compared to Actemra.

The policy specifies age thresholds, prior therapy requirements (such as failure of traditional DMARDs or inadequate response to NSAIDs/corticosteroids where applicable), TB screening requirements prior to initiation, dosing limits by indication and weight, restrictions on concomitant biologic DMARD use, and authorization/documentation expectations for continuation of therapy.

Definitions and Terms

inv-36: Negative TB test — screening prerequisite definition

DefinitionA negative tuberculosis (TB) screening test (e.g., purified protein derivative [PPD] or blood test) is required prior to initiation of tocilizumab therapy

Indications where requiredRequired prior to treatment for RA, systemic JIA, polyarticular JIA, and giant cell arteritis

Test examplesExamples include PPD skin test or TB blood test (interferon-gamma release assay)

inv-37: Severe or life-threatening cytokine release syndrome — definition

Definition of severe or life-threatening CRSHemodynamic instability despite IV fluids and vasopressor support OR worsening respiratory distress (pulmonary infiltrates, increasing oxygen requirement including high-flow oxygen and/or need for mechanical ventilation) OR rapid clinical deterioration

Age threshold for CRS coverage

Policy Summary

Payerblue cross blue shield - louisiana

Policytocilizumab intravenous Products

Policy CodePolicy MA-213

Change TypeNo material changes

Effective DateJul 1, 2026

Last ReviewApr 21, 2026

Next Review DateApr 21, 2026

Key ActionObtain prior authorization for initial and continuation therapy and document clinical benefit for continuation.

SourceLink

On This Page

Patient has a negative TB test (eg, PPD or blood test) prior to treatment

Dosing by weight: Patient meets ONE of: if <30 kg dose <=12 mg/kg every 2 weeks; OR if >=30 kg dose <=8 mg/kg every 2 weeks<=12 mg/kg q2w (<30 kg) OR <=8 mg/kg q2w (>=30 kg)

Continuation prerequisites: Continuation: patient has received initial authorization from the plan OR documentation of authorization from a previous plan; AND patient has experienced a beneficial clinical response from baseline (eg, resolution of fever, reduction in rash, normalization of inflammatory markers, decreased corticosteroid requirements, reduced joint symptoms); AND requested drug is NOT used concomitantly with other biologic DMARDs or specified agents; AND dosing remains within weight-based limits

TB screening: Patient has a negative TB test (eg, PPD or blood test) prior to treatment

Dosing by weight: Patient meets ONE of: if <30 kg dose <=10 mg/kg every 4 weeks; OR if >=30 kg dose <=8 mg/kg every 4 weeks<=10 mg/kg q4w (<30 kg) OR <=8 mg/kg q4w (>=30 kg)

Continuation prerequisites: Continuation: patient has received initial authorization from the plan OR documentation of authorization from a previous plan; AND patient has experienced a beneficial clinical response from baseline (eg, improved range of motion, reduced pain, decreased morning stiffness, improved function, reduced corticosteroid dose, improved inflammatory markers); AND requested drug is NOT used concomitantly with other biologic DMARDs or specified agents; AND dosing remains within weight-based limits

Failed treatment with systemic corticosteroid therapy unless contraindicated

Dose: Dosage is 6 mg/kg every 4 weeks6 mg/kg q4w

Continuation prerequisites: Continuation: patient received initial authorization from the plan OR documentation of authorization from a previous plan; AND patient has experienced a beneficial clinical response from baseline (eg, decreased headache, scalp or jaw pain, reduced fatigue, improved vision, reduced corticosteroid dosage, or improved inflammatory markers); AND requested drug is NOT given concomitantly with other biologic DMARDs or specified agents; AND dosage is 6 mg/kg every 4 weeks

Dosing is consistent with the specified regimen for the indication (eg, 6 mg/kg every 4 weeks for giant cell arteritis; 8 mg/kg every 4 weeks for adult RA; weight‑based pediatric dosing where applicable)

inv-21: Maximum per-infusion dose for CRS

Maximum per-infusion dose (CRS)No infusion to exceed 800 mg per infusion

Maximum total doses per CRS eventNo more than 4 total IV doses per CRS event

Applicable productsApplies to Actemra and listed biosimilars (Tofidence, Tyenne, Avtozma) for CRS

inv-22: Minimum interval between infusions for CRS

Minimum interval between infusionsInfusions should be at least 8 hours apart

Maximum dosing frequency contextNo more than 4 total doses per CRS event with >=8 hours between doses

Clinical rationaleInterval supports assessment of response and aligns with CRS management guidance

Documentation of previous plan authorization may be accepted for continuation.
Include indication-specific evidence of clinical improvement as described in continuation criteria.

Prior Authorization

All listed codes require prior authorization

Prior authorization is required for all HCPCS codes listed for IV tocilizumab (J3262, Q5133, Q5135, Q5156) to ensure appropriate utilization and alignment with clinical guidelines.

All codes listed on the Medical Policy require prior authorization.

Step Therapy

Document failure of conventional therapy (DMARD/NSAID/corticosteroid) when required

Document failure of conventional therapy when required by the indication: for rheumatoid arthritis and polyarticular JIA, record failure of one or more traditional DMARDs (e.g., methotrexate); for systemic JIA document inadequate response to NSAIDs or corticosteroids, unless contraindicated.

RA and polyarticular JIA: failed treatment with ≥1 traditional DMARD (examples listed include methotrexate).
Systemic JIA: inadequate response to NSAIDs or corticosteroids unless contraindicated.

Step Therapy

Step therapy expectations — document prior DMARD/NSAID/corticosteroid trials

For certain arthritis indications, document that the patient tried and had inadequate response to traditional DMARDs or NSAIDs/corticosteroids as specified in the selection criteria prior to initiating tocilizumab.

Rheumatoid arthritis: failed one or more traditional DMARDs prior to initiation.
Polyarticular JIA: failed ≥1 traditional DMARD prior to initiation.
Systemic JIA: inadequate response to NSAIDs or corticosteroids prior to initiation.

Note

No explicit step therapy sequence specified — document prior therapy and rationale

Note that the policy does not specify an explicit sequential step-therapy pathway; document the actual prior therapies tried and rationale if the sequence differs from typical expectations.

No explicit step-by-step sequence is defined in this portion of the document.
Provide clinical justification when the prior therapy sequence deviates from common practice.

Documentation Required

Authorization and clinical response documentation required

Include documentation that demonstrates prior authorization (initial authorization from this plan or authorization documentation from a previous plan) and provide clinical response measures showing benefit from baseline when requesting authorization.

Submit prior authorization reference/approval and supporting clinical notes.
Provide indication-specific measures of improvement (e.g., reduced joint pain, normalized inflammatory markers, resolution of fever or rash).

Documentation Required

Documentation for continuation — must show clinical benefit and dosing consistency

For continuation requests, supply evidence of clinical benefit from baseline consistent with the continuation criteria (indication-specific symptom or laboratory improvements) and confirm dosing remains within policy limits.

Document measurable clinical improvement as described for each indication.
Confirm continued dosing does not exceed the policy-specified limits (weight-based where applicable).

Documentation Required

Authorization documentation and transition — 90-day transition with prior plan authorization

If a patient transitions from another plan, provide the previous plan's authorization documentation to request a 90-day transition honor; the prior authorization must be for an ongoing course of treatment and services must otherwise be covered under this plan.

A 90-day transition period may be honored if documentation of the prior authorization from the previous plan is provided.
Services must be a covered service under the Blue Advantage plan for transition to apply.

Note

Confirm benefits and medical necessity — prerequisites to coverage

Verify member benefits and that medical necessity criteria are met before submitting a request; coverage may be denied if benefits are not available under the member's contract or medical necessity criteria are not satisfied.

Benefits must be available in the member's contract/certificate.
Medical necessity criteria and guidelines must be met for coverage.

Denial Risk

Denial risk if selection or continuation criteria unmet

Be aware that requests failing to meet the disease-specific patient selection or continuation criteria listed in the policy will be considered not medically necessary and may be denied.

Requests not meeting the listed selection or continuation criteria will be considered not medically necessary.
Continuation denials can be based on lack of documented beneficial clinical response.

Denial Risk

Risk of denial if prior authorization not obtained

Do not bill or furnish IV tocilizumab without obtaining prior authorization for the listed codes; services may be denied if authorization is not obtained.

All codes listed on the Medical Policy require prior authorization.
Services may be denied if prior authorization is not obtained.

Patient is 2 years of age or older

Treatment implicationSevere CRS meeting this definition may be eligible for tocilizumab per policy

inv-38: Actemra — brand definition and approval year

Brand nameActemra is the brand name for tocilizumab

First FDA approval yearFirst approved in 2010

Indications listedIndicated for RA, systemic JIA, polyarticular JIA, giant cell arteritis, CRS, systemic sclerosis-associated ILD, and hospitalized COVID-19

inv-39: Biosimilars (Tofidence, Tyenne, Avtozma) — biosimilar products and indication notes

Biosimilar productsTofidence (tocilizumab-bavi), Tyenne (tocilizumab-aazg), Avtozma (tocilizumab-anoh)

Indication alignmentBiosimilars are generally approved for the same IV indications as Actemra with indications largely aligned

Tofidence exceptionTofidence does not carry the cytokine release syndrome and systemic sclerosis-associated ILD indications